CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,632 enrolled
Drug / intervention
ELISA test for the antibodies to COVID-2019.other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05043142
NCT05043142N/ACompleted
CompareCT.gov

Exhaustive, Cross-sectional, Non-interventional, Multicenter Retrospective Epidemiological Study of the COVID-2019 Incidence and Prevention Methods of SARS, Including COVID-2019, Among Staff of Participating Organizations.

Yuria-Pharm·observational·Posted Sep 14, 2021·Updated Oct 1, 2021

In Brief

An observational study evaluating ELISA test for the antibodies to COVID-2019. for Covid19. Completed, enrolled 3,632 participants across 7 sites.

Detailed Summary

Exhaustive, cross-sectional, non-interventional, multicenter retrospective epidemiological study, case study aimed to determine the relationship between the systematic use of prophylactics to prevent SARS, including COVID-2019, and the risks of incidence and serious complications of COVID-2019 among staff of participating organizations.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUkraine
CollaboratorsPharmaxi LLC

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 14, 2021
Enrollment StartMar 16, 2021
Primary CompletionJun 23, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.8 years ago

Interventions

ELISA test for the antibodies to COVID-2019.other

Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.